Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 6, Issue 3, Pages 387-398Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/14737159.6.3.387
Keywords
amyotrophic lateral sclerosis; biomarker; mass spectrometry; metabolomics; proteomics; surrogate marker
Categories
Funding
- NIEHS NIH HHS [R21 ES013470] Funding Source: Medline
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. ALS is a fatal neurodegenerative disease and clinical diagnosis typically takes many months to complete. Early disease diagnosis through the use of biomarkers may aid in correct clinical management of patients and possibly delay time to ventilator and morbidity. This review explores the progress of biomarker discovery efforts for ALS and the many challenges that remain. Included are different technologies utilized in biomarker discovery efforts (proteomic, genomic and metabolomic) and putative biomarkers uncovered using these techniques. These studies have discovered genetic mutations leading to familial forms of ALS, and specific protein alterations that occur in biological fluids (cerebrospinal fluid and blood) and/or tissues of ALS subjects. More recent high-throughput technologies have revealed panels of proteomic or metabolic biomarkers that can discriminate between ALS and control groups. The identification of disease-specific biomarkers will provide opportunities to develop early diagnostic measures as well as surrogate markers to monitor disease progression and test drug efficacy in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available